ozempic is the brand name for semaglutide FDA crackdown on off-brand products set to take effect, threatening supply and access many Why weight-loss drugs became more

The amylin mechanism fills a critical gap in weight loss therapeutics that GLP-1s alone cannot address, explaining the exceptional results seen with dual-pathway combinations

Sacroiliitis is one of those conditions that hides in plain sight especially after trauma, repetitive loading, or inflammatory arthropathies and it loves to masquerade as facet pain, discogenic pain, or even hip pathology

you can also search for UK trials via NIHR Be Part of Research (www.bepartofresearch.nihr.ac.uk) Do not discontinue any existing prescribed medication (such as semaglutide or tirzepatide) in anticipation of retatrutide becoming available For clinicians: Familiarise yourself with the LY3437943 development code and ongoing Phase 3 trial data, as patients may present with questions informed by media coverage Be prepared to discuss the distinction between investigational and approved therapies , and the importance of evidence-based prescribing Monitor MHRA and NICE communications for updates on regulatory submissions and technology appraisals From a safety perspective, the adverse effect profile observed in Phase 2 trials (as reported in the 2023 New England Journal of Medicine publication) was broadly consistent with other GLP-1-based therapies, with nausea, vomiting, diarrhoea, and decreased appetite being the most commonly reported side effects

Weight-loss injections are a pathway to a healthier lifestyle